Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CDMO Avid Bioservices, Inc.

Post-Market Trading 11-22 19:36:10 EST

12.30

+0.05

+0.41%

盘后12.28

-0.02-0.18%

17:20 EST

High12.30	Low12.25	Vol2.22M
Open12.29	D1 Closing12.25	Amplitude0.41%
Mkt Cap786.66M	Tradable Cap666.05M	Total Shares63.96M
T/O27.26M	T/O Rate4.10%	Tradable Shares54.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.3,"timestamp":1732309200000,"preClose":12.25,"halted":0,"volume":2222738,"hourTrading":{"tag":"盘后","latestPrice":12.2782,"preClose":12.3,"latestTime":"17:20 EST","volume":52395,"amount":644441.2096500001,"timestamp":1732314001008},"delay":0,"floatShares":54150153,"shares":63955784,"eps":-2.276774,"marketStatus":"Post-Market Trading","change":0.05,"latestTime":"11-22 19:36:10 EST","open":12.29,"high":12.3,"low":12.25,"amount":27264237.67228,"amplitude":0.004082,"askPrice":12.28,"askSize":230,"bidPrice":12.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.276774,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.25,"preHourTrading":{"tag":"盘前","latestPrice":12.29,"preClose":12.25,"latestTime":"09:29 EST","volume":100,"amount":1229,"timestamp":1732285792088},"postHourTrading":{"tag":"盘后","latestPrice":12.2782,"preClose":12.3,"latestTime":"17:20 EST","volume":52395,"amount":644441.2096500001,"timestamp":1732314001008},"volumeRatio":1.077325,"impliedVol":0.5312,"impliedVolPercentile":0.1786},"requestUrl":"/m/hq/s/CDMO/tweets","defaultTab":"tweets","newsList":[{"id":"2485423442","title":"Lifecore Biomedical Hosts Virtual Investor Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423442","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485423442?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:17","pubTimestamp":1732223820,"startTime":"0","endTime":"0","summary":"Vida Strategic Partners. Stephanie Diaz (Investors). 415-675-7401. sdiaz@vidasp.com. Tim Brons (Media). 415-675-7402. tbrons@vidasp.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985638/23089/en/Lifecore-Biomedical-Hosts-Virtual-Investor-Day.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDMO","BK4212","BK4139","LFCR"],"gpt_icon":1},{"id":"2485499125","title":"BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485499125","media":"Newsfile","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485499125?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:30","pubTimestamp":1732195800,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia and Rehovot, Israel-- - BioHarvest Sciences Inc.    , a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place on December 3, 2024.CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the event and will host a presentation for in-person attendees. Following the conference, a link to the presentation will be shared on the BioHarvest investor relations website.Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cau","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/029ZHwio9j72BHuATxoVfQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/b5566c2fac1c740989d748168f38d1d8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/029ZHwio9j72BHuATxoVfQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/b5566c2fac1c740989d748168f38d1d8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioharvest-sciences-participate-noble-capital-133000213.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioharvest-sciences-participate-noble-capital-133000213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDMO","NBL","BK4139","BK4183","BHST"],"gpt_icon":1},{"id":"2484197375","title":"OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2484197375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484197375?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:00","pubTimestamp":1732104000,"startTime":"0","endTime":"0","summary":"OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024:OXB (LSE: OXB), a quality and innovatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984302/0/en/OXB-to-host-a-free-webinar-on-accelerating-development-of-viral-vectors-through-automated-manufacturing-and-analytical-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO"],"gpt_icon":0},{"id":"2484943020","title":"Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484943020?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:30","pubTimestamp":1732019400,"startTime":"0","endTime":"0","summary":"New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that align with BIOSECURE Act goals to onshore and str","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/19/2983474/32418/en/Scorpius-Holdings-Launches-Scorpius-Ventures-to-Support-U-S-Biotech-Innovation-through-Flexible-Equity-Based-Onshoring-Model.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","BK4215","BK4588","EQR","BK4585"],"gpt_icon":0},{"id":"2484186654","title":"Avid Bioservices, Inc. (CDMO): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2484186654","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484186654?lang=en_us&edition=fundamental","pubTime":"2024-11-18 05:52","pubTimestamp":1731880323,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Avid Bioservices, Inc.  on Twitter by northeasternsvf. In this article, we will summarize the bulls’ thesis on CDMO. Avid Bioservices, Inc. 's share was trading at $12.20 as of Nov 13th. CDMO’s trailing and forward P/E were 9.41 and 88.50 respectively according to Yahoo Finance.A scientist researching the innate and adaptive immune response in a biopharmaceutial laboratory.Avid Bioservices, Inc., a contract development and manufacturing organization  specializing in biopharmaceuticals derived from mammalian cell cultures, is positioned for significant growth driven by both market developments and legislative tailwinds. The company offers a range of services, including process development, clinical and commercial manufacturing, and regulatory support, focusing on biologics like monoclonal antibodies and recombinant proteins. Avid operates a state-of-the-art facility in California, capable of managing both small and large-scale production for a wide array","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bBE2KNxt_Q7rzxG7R0xO5g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/09b5ce08155649d04db4c2ccd2220990","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bBE2KNxt_Q7rzxG7R0xO5g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/09b5ce08155649d04db4c2ccd2220990"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avid-bioservices-inc-cdmo-bull-215203227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CDMOP","CTLT","CDMO"],"gpt_icon":0},{"id":"2483376783","title":"Here’s Why Greenhaven Road Capital Invested in Lifecore Biomedical (LFCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483376783","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483376783?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:44","pubTimestamp":1731678247,"startTime":"0","endTime":"0","summary":"Greenhaven Road Capital, an investment management company, released its third-quarter 2024 investor letter. A copy of the letter can bedownloaded here. The Fund returned approximately +15% in the third quarter, bringing year-to-date returns to approximately +12% net. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc.  in its Q3 2024 investor letter:. Lifecore Biomedical, Inc.  is not on our list of31 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held Lifecore Biomedical, Inc.  at the end of the second quarter which was 14 in the previous quarter. In the fiscal first quarter of 2025, Lifecore Biomedical, Inc.  generated $24.7 million in revenues compared to $24.5 million for","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s4SVeTl9O4EdlmVUGmrvsA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2773ebcf4562e27d82213ee11f7f62fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s4SVeTl9O4EdlmVUGmrvsA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2773ebcf4562e27d82213ee11f7f62fc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-greenhaven-road-capital-invested-134407693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","LFCR","PSQ","BK4212","NQmain",".IXIC","BK4139","TQQQ","MNQmain","SQQQ","CDMO","QLD","QID"],"gpt_icon":1},{"id":"2483794359","title":"Punch and Associates: Intends to Vote Against Proposed Acquisition of Avid Bioservices by Gho Capital and Ampersand Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2483794359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483794359?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:40","pubTimestamp":1731624027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1NS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CDMO"],"gpt_icon":0},{"id":"2483359797","title":"Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483359797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483359797?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:40","pubTimestamp":1731624027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2483330312","title":"Press Release: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483330312","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483330312?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:15","pubTimestamp":1731618900,"startTime":"0","endTime":"0","summary":"Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability. DURHAM, N.C., Nov. 14, 2024  -- Scorpius Holdings, Inc  , an integrated contract development and manufacturing organization , today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.Wolf added, \"The new clients we onboarded this quarter demonstrate Scorpius' reputation as a trusted biomanufacturing partner for early-stage and clinical development. These agreements further highlight our ability to support companies with secure, U.S.-based solutions for development and manufacturing needs. These partnerships are indicative of our growing influence in the industry and our role as a resource for companies seeking flexible, responsive CDMO services.\". Concluding, Wolf stated, \"Our future looks promising with a weighted average pipeline of business development opportunities now exceeding $100 million a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCPX","PRGS","BK4139","BK4097","CDMO","LU2065732104.USD"],"gpt_icon":0},{"id":"2483012877","title":"Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225","url":"https://stock-news.laohu8.com/highlight/detail?id=2483012877","media":"GlobeNewswire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483012877?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:05","pubTimestamp":1731589500,"startTime":"0","endTime":"0","summary":"NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs FLORHAM PARK, N.J., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981164/29076/en/Cellectar-Biosciences-and-NorthStar-Medical-Radioisotopes-Announce-Partnership-for-Supply-of-Actinium-225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","CLRB"],"gpt_icon":1},{"id":"2483487702","title":"Integer to Present at Piper Sandler Healthcare Conference on Dec. 3, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483487702","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483487702?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"PLANO, Texas, Nov.  14, 2024  (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981110/26755/en/Integer-to-Present-at-Piper-Sandler-Healthcare-Conference-on-Dec-3-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","CDMO","GRO","ITGR","BK4137","LU0128526141.USD","BK4139","LU1169589451.USD","LU0566484027.USD","LU0029874061.USD","LU1169590202.USD","BK4082","LU1559883803.SGD"],"gpt_icon":0},{"id":"2483848308","title":"Meiji Seika Pharma Announces Investment in ARCALIS, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848308","media":"Business Wire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483848308?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:00","pubTimestamp":1731564000,"startTime":"0","endTime":"0","summary":"TOKYO, November 14, 2024----Meiji Seika Pharma Co., Ltd.  today announced its investment in ARCALIS, Inc. .ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companies, and Arcturus Therapeutics, Inc. a commercial mRNA medicines and vaccines company. ARCALIS is engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organization  services. The company plans to establish a comprehensive system for the domestic production of mRNA vaccines, ranging from the development of manufacturing technologies to the production of both active pharmaceutical ingredients and formulations.In response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic, ARCALIS and Meiji Seika Pharma are committed to advancing the development, production, and supply of mRNA vaccines in line with the \"Strategy for Strengthening Vac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiji-seika-pharma-announces-investment-060000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","CDMO","BK4139"],"gpt_icon":0},{"id":"2483885712","title":"BRIEF-Brock Pond Capital Partners Urges Avid Bioservices To Remain Standalone Public Company Absent Improved Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483885712","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483885712?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:12","pubTimestamp":1731507163,"startTime":"0","endTime":"0","summary":"BRIEF-Brock Pond Capital Partners Urges Avid Bioservices To Remain Standalone Public Company Absent Improved OfferNov 13 (Reuters) - Avid Bioservices Inc CDMO.O:BROCK POND CAPITAL PARTNERS: URGES AVID","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK1LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2483885759","title":"Brock Pond Capital Partners: Does Not Intend to Vote for Avid Bioservices Deal With Gho/Ampersand","url":"https://stock-news.laohu8.com/highlight/detail?id=2483885759","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483885759?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:11","pubTimestamp":1731507110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK1LN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CDMO"],"gpt_icon":0},{"id":"2483852228","title":"Brock Pond Capital Partners: Urges Avid Bioservices to Remain Standalone Public Company Absent Improved Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483852228","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483852228?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:11","pubTimestamp":1731507110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK1LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2483579310","title":"Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2483579310","media":"GlobeNewswire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483579310?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  12, 2024  (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979725/24825/en/Codexis-Announces-Appointment-of-Raymond-De-Vr%C3%A9-PhD-to-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","CDXS","BK4121","BK4139"],"gpt_icon":1},{"id":"2483057773","title":"Lifecore Biomedical to Present at Stephens Annual Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2483057773","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483057773?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"CHASKA, Minn., Nov.  12, 2024  (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979724/23089/en/Lifecore-Biomedical-to-Present-at-Stephens-Annual-Investment-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFCR","BK4139","CDMO","BK4212","BK4121"],"gpt_icon":1},{"id":"2482782254","title":"Press Release: Longeveron(R) Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482782254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482782254?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:05","pubTimestamp":1731333900,"startTime":"0","endTime":"0","summary":"Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls . MIAMI, Nov. 11, 2024  -- Longeveron Inc. , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer  and Senior Vice President of Chemistry, Manufacturing, and Controls , effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies.\"I am thrilled to join Longeveron as the CTO and SVP of CMC,\" said Mr. Blass. \"Longeveron's commitment to advancing regenerative medicine aligns with my passion for developing innovative therapies. I look forward to contributing to the Company's mission and driving forward our technological and manufacturing strategies to bring transformative treatments to patients.\". Longeveron is a clinical stage biotechnology company developing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4585","IE00BHPRN162.USD","LU0971096721.USD","CMC","LU0267386448.USD","MSC","BK4555","IE00B1BXHZ80.USD","CDMO","R","IE00BKVL7J92.USD","BK4099","BK4232","BK4022","BK4139","LGVN","CTO","03160","BK4006","LU0149725797.USD","BK4160","LU0882574139.USD","TM","WRD","BK4588","IE00BZ1G4Q59.USD","LU1363072403.SGD","LU0170899867.USD","BK4575"],"gpt_icon":0},{"id":"2482497128","title":"Avid Bioservices: Take-Private Deal At A Reasonable Price, Maintaining Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2482497128","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482497128?lang=en_us&edition=fundamental","pubTime":"2024-11-09 13:03","pubTimestamp":1731128600,"startTime":"0","endTime":"0","summary":"Since my \"Strong Buy\" article on Avid in May, my prediction of a potential take-private has come to fruition with Ampersand and GHO purchasing Avid at a 20% premium .I believe it is an amazing deal at a reasonable price  given Avid's business model appeal, numerous tailwinds, catalysts, and PE interest in the space.I also believe Ampersand and GHO are perfect buyers for Avid, given their strong track record with CDMOs and potential for value creation.As an investor in Avid, I am optimistic about the deal closing in 1Q25 and will hold my shares to receive the $12.5 per share offer.   bee32/iStock via Getty Images  Back on May 16 this year, I published a Strong Buy on Avid Bioservices , with one of my catalysts being a potential take-private. At the time of writing, Avid was trading at $8.67 per share. Fast-forward","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/878022446/image_878022446.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/878022446/image_878022446.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4735309-avid-bioservices-my-strong-buy-pays-off-1-1bn-take-private","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2481815964","title":"Deals of the day-Mergers and acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2481815964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481815964?lang=en_us&edition=fundamental","pubTime":"2024-11-08 04:48","pubTimestamp":1731012490,"startTime":"0","endTime":"0","summary":"Deals of the day-Mergers and acquisitionsAdds Ayvens; updates Banco BPMNov 7 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** Ayvens AYV.PA,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME2MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIG.AU","CDMO","BK4139","BK7103"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0.0268},{"period":"1month","weight":0.1745},{"period":"3month","weight":0.1578},{"period":"6month","weight":0.4016},{"period":"1year","weight":1.2518},{"period":"ytd","weight":0.8846}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.633333,"avgChangeRate":0.252871},{"month":2,"riseRate":0.566667,"avgChangeRate":0.058259},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073281},{"month":12,"riseRate":0.4,"avgChangeRate":0.024422}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avid Bioservices, Inc.(CDMO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avid Bioservices, Inc.(CDMO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}